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The systemic administration of lipopolysaccharide (LPS) induces time-dependent behavioral alterations,
which are related to sickness behavior and depression. The time-course effects of LPS on prepulse
inhibition (PPI) remain unknown. Furthermore, the time-dependent effects of LPS on central nitrite
content had not been investigated. Therefore, we studied alterations induced by single LPS (0.5 mg/kg,
i.p.) administration to mice on parameters, such as PPI, depressive- and anxiety-like behaviors, working
memory, locomotor activity and motor coordination, 1.5 and 24 h post-LPS administration. IL-1β and
TNFα in the blood and brain as well as brain nitrite levels were evaluated in the prefrontal cortex (PFC),
hippocampus (HC) and striatum (ST). An overall hypolocomotion was observed 1.5 h post-LPS, along with
depressive-like behaviors and deﬁcits in working memory. Increments in IL-1β content in plasma and
PFC, TNFα in plasma and decreases in nitrite levels in the ST and PFC were also veriﬁed. Twenty-four
hours post-LPS treatment, depressive-like behaviors and working memory deﬁcits persisted, while PPI
levels signiﬁcantly reduced along with increases in IL-1β content in the PFC and a decrease in nitrite
levels in the HC, ST and PFC. Our data demonstrate that a delayed increase (i.e., 24 h post-LPS) in PPI
levels ensue, which may be useful behavioral parameter for LPS-induced depression. A decrease in
nitrergic neurotransmission was associated with these behavioral ﬁndings.
& 2013 Elsevier B.V. All rights reserved.1. Introduction
Over-activation of the innate immune system and abnormal
secretion of inﬂammatory mediators (e.g., cytokines) have
been implicated in the physiopathology of depression (Dellagioia
et al., 2012; Dunjic-Kostic et al., 2012; Dunn and Swiergiel,
2005; Dunn et al., 2005) and it has been proposed that treatment
with lipopolysacharide (LPS) or interleukin-1 (IL-1) could induce
time-dependent depressive-like behavioral in rodents (Dunn et al.,
2005).
Whether depression is a form or consequence of sickness
behavior has been highlighted as a question of considerablell rights reserved.
rá, Department of Physiology
, 60431-270 Fortaleza, Ceara,
.translational importance (Maes et al., 2012a). In fact, there are
considerable phenomenological similarities between sickness
behavior and depression; behavioral inhibition, anorexia, weight
loss, anhedonia, physio-somatic (fatigue, hyperalgesia, malaise)
symptoms, anxiety and neurocognitive impairment can be char-
acteristic of both conditions.
Some studies have identiﬁed time-related behavioral altera-
tions induced by systemic LPS administration (Dantzer et al., 2008;
Fu et al., 2010). It has been suggested that short-term behavioral
alterations (i.e., during the peak secretion of cytokines) are related
to sickness behavior, while long-term depressive behavior is
pathophysiologically linked to depression (Dantzer et al., 2008).
Possibly the most compelling evidence implicating cytokines in
depressive illness comes from the induction of depressive-like
behavior following treatment with endotoxin or recombinant
cytokines, such as interleukin-2 (IL-2) and interferon-α (IFN-α)
(Capuron and Dantzer, 2003). This includes alterations in neuro-
transmitter function and neuroendocrine output (Dunn, 2006)
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2002; Capuron and Dantzer, 2003). Moreover, healthy volunteers
treated with LPS report a decrease in positive mood and increase
in anxiety (Grigoleit et al., 2011; Kullmann et al., 2012). Taken
together, these studies support the utility of the LPS-induced
animal model of depression.
Animal models of depression, such as the separation-induced
model, promote traditional depressive-like behavior together with
a decrease in prepulse inhibition (PPI) levels (Martin and Brown,
2010). This decrease in PPI levels observed in preclinical models
of depression may be related to stress-induced increases in
corticotropin-releasing hormone levels (Tejeda et al., 2010), which
are observed in depressed subjects (Bangasser and Valentino,
2012). There is also evidence to suggest cytokines may impair
PPI (Mizuno et al., 2007). To our knowledge, changes in PPI levels
24 h post systemic LPS treatment have not been investigated.
Nitrergic signaling is involved in the neurobiology of stress-
related psychiatric disorders such as anxiety and depressive
disorders (Zhou et al., 2007). In the chronic mild stress depression
model hippocampal production of nitric oxide (NO) by neuronal
nitric oxide synthase isoform (nNOS) is altered (Palumbo et al.,
2007; Zhou et al., 2007). However, an association between
LPS-induced depression and central alterations in nitrite levels
has yet to be reported.
Following previously reported LPS-induced time-dependent
behavioral alterations (Dantzer et al., 2008), we investigate the
time-course of behavioral changes (depressive/anxiety-like behaviors
and alterations in PPI levels) induced by a single systemic adminis-
tration of LPS to adult mice, as well as the associated changes in
cytokine (IL-1β and TNFα) and nitrite content in brain areas puta-
tively related to affective symptoms (Drevets et al., 2008); the
prefrontal cortex (PFC), hippocampus (HC) and striatum (ST).2. Materials and methods
2.1. Drugs
Lipopolysaccharide (LPS) from Escherichia coli, strain 055:B5
(Sigma-Aldrich Corp., St Louis, USA) and ketamine (Cristália Chemical
and Pharmaceutical Products, Itapira, Brazil) were used. Drugs were
freshly prepared. All other chemicals used were of analytical grade.
2.2. Animals
The experiments were performed in male Swiss mice (weighting
20–30 g) obtained from the Animal House of Federal University of
Ceará. The animals were housed 10 per cage in standard poly-
carbonate cages (4220.520 cm) and standard environmental
conditions (2271 1C; humidity 6075%; reversed 12-h light/dark
cycle with lights on at 19:00) with access to food (FRI-LAB Rat II,
FRI-Ribe) and water ad libitum. All experimental procedures were
conducted between 8:00 and 14:00 h and carried out in accordance
with the NIH Guide for the Care and Use of Laboratory Animals
(NIH, 2011) and the Brazilian College of Animal Experimentation
(COBEA). The research protocol was approved by the local ethical
committee of Federal University of Ceará.
2.3. Experimental design
The dose of LPS was chosen based on previous studies evaluat-
ing LPS-induced behavioral and neurochemical alterations in mice
(Kessler et al., 2003; Lejuez et al., 2011). In the case of ketamine,
the dose selection was based on studies using this drug as an animal
model of schizophrenia (de Araujo et al., 2011). The animals were
randomly divided into two experimental groups: LPS-treated group(LPS 0.5 mg/kg, i.p., dissolved in 0.2 ml of volume, n¼32) and control
group (n¼32, i.p., injected with 0.2 ml of vehicle - sterile endotoxin-
free PBS). To avoid potential inﬂuence of behavioral testing on
cytokine levels, cytokine assays and behavioral testing were per-
formed on different animals (Bossu et al., 2012). Behavioral testing
and cytokine analyses were performed in controls and after LPS
challenge at two time-points (1.5 and 24 h). Different animals were
used at each time-point. One additional group of mice (n¼8)
received a single sub-anesthetic dose of ketamine (20 mg/kg, i.p.)
and PPI levels were evaluated. The behavioral assessments were
performed on four distinct different animal group; (1) open ﬁeld,
plus maze and rota rod tests in that order; (2) forced swimming test;
(3) the Y-maze and (4) PPI determinations. In all behavioral deter-
minations, the rater was blind to the experimental treatment.
After each time-point of observation the animals used for
cytokines and nitrite determinations were killed by cervical
dislocation. Blood was immediately collected, centrifuged and
the plasma isolated for posterior analyses. The brain areas dis-
sected were: prefrontal cortex (PFC), hippocampus (HC) and
striatum (ST). All biological material was immediately stored at
−70 1C until assay.
2.4. Behavioral determinations
2.4.1. Open ﬁeld test (OFT)
To analyze the effects of LPS treatment on locomotor activity,
animals were evaluated in an open ﬁeld test. The arena was made
of acrylic (406050 cm) with the ﬂoor divided into nine equal
squares. The exploratory activity of the animal was registered
during 5 min (Archer, 1973). The number of squares crossed by the
animal and number of groomings (stereotyped behavior) and
rearings (vertical exploratory activity) were observed. The experi-
ments were conducted in a sound-attenuated room, under low-
intensity red light.
2.4.2. Rota rod test (RRT)
The rota rod test was used to evaluate motor coordination.
In this test, animals were placed with the four paws on a rotating
swivel 25 cm above the ﬂoor, turning at 12 rpm (Ugo Basile, Italy).
For each animal, the number of falls (up to three falls) during
1 min was registered (Dunham and Miya, 1957).
2.4.3. Forced swimming test (FST)
The mice were individually placed into an acrylic cylinder
(25 cm height, 10 cm diameter) containing 8 cm of water main-
tained at 22–24 1C. After 1 min of habituation the time of immo-
bility (s) of the animals was rated during 5 min in a total time of
6 min inside the cylinder. Immobility was deﬁned as the absence
of active, escape-oriented behaviors such as swimming, jumping,
rearing, snifﬁng, or diving (Porsolt et al., 1978). Any mouse
appearing to have difﬁculty keeping its head above water was
removed from the cylinder and excluded from the study. The
procedure has been validated in our laboratory by demonstrating
that imipramine treatment (10 mg/Kg, i.p.) dramatically decreases
immobility time (data not shown).
2.4.4. Elevated plus maze test (EPM)
The elevated plus maze consisted of two open (305 cm) and
two darkened, closed arms (30515 cm) emanating from a
common central platform (55 cm) to form a plus shape. The
entire apparatus was raised 45 cm above its base, and the test was
made under dim red light (260 W). The test commenced by
placing a mouse on the central platform, facing an open arm. A
5 min observation period was used, during which total arm
entries, and the amount of time spent by the animals in open
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Fig. 1. Number of crossings (A), rearings (B) and groomings (C) 1.5 and 24 h after
lipopolysaccharide (LPS) 0.5 mg/kg, i.p. administration (n¼8–10 animals for each
group). Bars represent means7standard error of means (S.E.M.) of the number of
crossings, rearings or groomings; *Po0.05 vs. control (1.5 h), &Po0.05 vs. control
(24 h) according to Student's t test.
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% open entries (i.e., open entries/total entries100) and % time in
open and closed arms. The procedure has been validated in our
laboratory by demonstrating that diazepam treatment (1 mg/kg,
i.p.) increases the proportion of open arm entries and total time
spent in the open arms (data not shown).
2.4.5. Prepulse inhibition of startle (PPI)
The mice were placed in a stabilimeter, which consisted of a wire-
mesh cage (844.5 cm) suspended within a PVC frame
(2599 cm) attached to the response platform with four
thumbnail-screws. The stabilimeter and platform were located inside
a ventilated plywood sound attenuating chamber (646040 cm)
(Insight, São Paulo, Brazil). The ﬂoor of the stabilimiter consisted of six
stainless steel bars. The startle reaction of the animals generated a
pressure on the response platform and analogue signals were
ampliﬁed, digitized and analyzed by a software of the startle measure
system (Insight, São Paulo, Brazil), which also controlled other
parameters of the session (intensity of the acoustic stimulus, inter-
stimulus interval, etc.). Two loudspeakers located 10 cm above the
ﬂoor, on each lateral side of the acoustic isolation chamber, were used
to deliver the prepulse stimulus, the acoustic startle stimulus and
continuous background noise (65 dB). Calibration procedures were
conducted before the experiments to ensure equivalent sensitivities of
the response platforms over the protocol.
The test session began by placing a subject in the stabilimeter
cage for a 5 min exposure to the background noise. After this
acclimatization period, the subject was presented with a series of
10 stimuli (pulse alone—120 dB, 50 ms duration), with an inter-
trial interval of 15 s. The purpose of this phase was to allow
within-session habituation to the startle stimulus. Thereafter, the
PPI modulation of the acoustic startle was tested in 74 trials
pseudo-randomly divided into seven different categories pre-
sented with an inter-trial interval of 15 s: 20 presentations of
pulse alone (120 dB, 50 ms duration), 8 presentations of each
prepulse intensity alone (70, 75 and 80 dB, 3000 Hz frequency,
20 ms duration) and 10 presentations of each prepulse intensity
+pulse (with 50 ms interval) (Blaszczyk et al., 2000; Gururajan
et al., 2010). Mean amplitude of startle response to pulse-alone
(P) and prepulse-pulse (PP+P) trials were calculated for each
subject. The PPI level of each mouse was determined by expressing
the prepulse+pulse startle amplitude as a percentage decrease
from pulse-alone startle amplitude, according to the following
formula: % PPI¼100−[100 (PP/P)]. Using this formula, a 0% value
denotes no difference between amplitude of startle response to
pulse alone and to the prepulse+pulse and, consequently, no PPI.
2.4.6. Y-maze
Immediate working memory performance was assessed by
recording spontaneous alternation behavior during a single ses-
sion in a Y maze (Hughes, 2004). Each mouse, new to the maze
(30 cm long by 6 cmwide by 20 cm high), was placed at the end of
one arm and allowed to move freely through the maze during an
8 min session. The series of arm entries was recorded visually.
Alternation was deﬁned if mice entered different arms three times
in succession from the results of consecutive arm entering.
The percentage of correct alternation was calculated as follows:
total of alternations/(total arm entries−2), as described elsewhere
(Dall'Igna et al., 2007).
2.5. Neurochemical determinations
2.5.1. ELISA for IL1-β and TNFα
The brain areas (PFC, HC and ST) were homogenized in eight
volumes of PBS buffer with protease (EMD Biosciences) andphosphatase (Sigma-Aldrich) inhibitors and centrifuged (10,000 rpm,
5 min). Plasma was used without dilution. The concentration of the
cytokines in 50 ml samples was determined by ELISA (R&D systems,
Minneapolis, MN, USA), following manufacturer's directions and
expressed in pg/g tissue.2.5.2. Nitrite assay
This determination was based on the method described by Green
et al. (1982). The assay was based on the Griess reaction to determine
C.S. Custódio et al. / European Journal of Pharmacology 713 (2013) 31–3834the production of NO. Brieﬂy, 100 ml of the supernatant was
incubated with 100 ml of the Griess reagent which consisted of
equal parts (1:1:1:1) of 1% sulfanilamide dissolved in 1% H3PO4, 0.1%
N-(1-naphthyl)-thylenediamine dihydrochloride and distilled water at
room temperature for 10 min. The absorbance was measured at
560 nm in a microplate reader. Nitrite content was determined from
a standard nitrite curve generated by using NaNO2 (ranging from 0.75
to 100 mM) as standard and was expressed as nM/g tissue.C LPS 0.5 C LPS 0.5
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Fig. 3. Behavioral determinations 1.5 and 24 h after LPS administration in EPM. The para
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Fig. 2. Immobility time in the forced swimming test (FST) 1.5 and 24 h after
lipopolysaccharide (LPS) 0.5 mg/kg, i.p. administration (n¼8–10 animals for each
group). Bars represent means7standard error of means (S.E.M.) of the immobility
time in seconds; nPo0.05 vs. control (1.5 h), &Po0.05 vs. control (24 h) according
to Student's t test.2.6. Statistical analyses
Data from behavioral and neurochemical determinations are
presented as mean7S.E.M. (standard errors of the mean) and were
compared with controls using Student's t-test. For the analyses of the
PPI produced by the three different prepulse intensities, repeated
measures two-way ANOVA with “experimental groups” and “prepulse
intensities” as factors was used, with Bonferroni test for post hoc
comparisons. The signiﬁcance level was set at p≤0.05. The statistical
program used was GraphPad Prism 5.0 Version for Windows,
GraphPad Software (San Diego, CA, USA).3. Results
The analyses of OFT data, presented in Fig. 1(A–C), showed that
1.5 h after LPS administration there was a signiﬁcant decrease in all
parameters evaluated, i.e., number of crossings (t¼8.976, df¼23,
Po0.0001), number of rearings (t¼3.654, df¼10, P¼0.0044) and
groomings (P¼0.035) when compared to control animals. Twenty
four hours post-LPS treatment only the decrease in grooming
behavior in relation to control animals was observed (t¼7.076,
df¼8, Po0.0001). The evaluation of motor coordination by the RRT
presented no signiﬁcant alterations at any time of observation (data
not shown).
Increments in the immobility time were observed in the FST 1.5 h
(t¼2.322, df¼10, P¼0.0427) and 24 h (t¼4.102, df¼11, P¼0.018)
after LPS administration (Fig. 2) when compared to control animals. In
the EPM test a signiﬁcant decrease in the number of open arms
entries (t¼2.809, df¼24, P¼0.0097) (Fig. 3A), total number of arms
entries (t¼2.351, df¼10, P¼0.0406) (Fig. 3B) and total time spent inC LPS 0.5 C LPS 0.5
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after LPS treatment when compared to control animals. The relation
between open/total entries did not change among experimental
groups (Fig. 3C).
The analyses of PPI data by repeated measures two-way ANOVA
revealed a signiﬁcant main effect of “prepulse intensities” (df¼2,
F¼13.2, Po0.0001) and “experimental groups” (df¼2, F¼16.85,
Po0.0001). Bonferroni post hoc test showed a signiﬁcant decrease
in PPI levels 24 h post-LPS treatment using the prepulse intensities
of 75 (Po0.05) and 80 dB (Po0.01) in relation to control animals.
Ketamine treatment (20 mg/kg) administration caused a signiﬁ-
cant decrease in PPI values in all prepulse intensities evaluated.
When compared to controls the decrease was signiﬁcant in the
prepulse intensities of 70, 75 and 80 dB (Po0.001), while when
compared to data from animals evaluated 24 h after LPS challenge
the signiﬁcance occurred in the prepulse intensities of 75 and70 dB 75 dB 80 dB
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Fig. 4. Percent of prepulse inhibition of startle (PPI) using three different prepulse
intensities (70, 75 and 80 dB) 1.5 and 24 h after lipopolysaccharide (LPS) 0.5 mg/kg,
i.p. administration (n¼8–10 animals for each group). Bars represent means7stan-
dard error of means (S.E.M.) of the percent of PPI; *Po0.05 vs. control and &Po0.05
vs. LPS 0.5 mg/kg for comparisons on each prepulse intensity according to Student's
t test.
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administration (n¼8–10 animals for each group). Bars represent means7standard error
to Student's t test.80 dB (Po0.001) (Fig. 4). The spatial working memory was
evaluated by the Y-maze spontaneous alternation task and animals
treated with LPS presented a signiﬁcant decrease on the percen-
tage of correct alternations 1.5 h (t¼5.867, df¼12, Po0.0001) and
24 h (t¼5.363, df¼15, Po0.0001) after the endotoxin adminis-
tration when compared to control animals (data not shown).
The levels of the cytokines IL-1β and TNFα in the plasma and
PFC were tested at the two-time points following LPS treatment
(Fig. 5). The content of IL-1β signiﬁcantly increased only 1.5 h post-
LPS challenge in plasma and 1.5 h and 24 h in the PFC (t¼4.158,
df¼12, P¼0.013) in relation to controls (Fig. 5A and B). The levels
of IL-1β in the HC and ST were unchanged when compared to
control animals (data not shown). On the other hand, TNFα levels
signiﬁcantly increased only 1.5 h after LPS administration in the
plasma (Fig. 5C) when compared to control group (1.5 h: t¼8.661,
df¼13, Po0.0001). No changes in TNFα content were observed in
the PFC (Fig. 5D), as well as in the HC and ST (data not shown).
Nitrite levels decreased in the HC only 24 h after LPS administra-
tion (t¼3.535, df¼9, P¼0.0064), while in the ST and PFC this
decrease occurred 1.5 h (ST: t¼4.746 df¼13, P¼0.0004; PFC:
t¼13.60, df¼8, Po0.0001) and 24 h (ST: t¼2.859 df¼11,
P¼0.0155; PFC: t¼8.909, df¼10, Po0.0001) following LPS admin-
istration when compared to controls (Fig. 6).4. Discussion
The results presented here corroborate previous ﬁndings of time-
dependent behavioral alterations induced by LPS (Dantzer, 2009;
Dantzer et al., 2008) and identify a decrease in PPI levels and nitrite
content in mood regulating brain areas of LPS-treated mice at 24 h
post-treatment. Increased IL-1β levels are also found in the PFC 24 hPrefrontal
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after lipopolysaccharide (LPS) 0.5 mg/kg, i.p. administration (n¼8–10 animals for
each group). Bars represent means7standard error of means (S.E.M.); nPo0.05 vs.
control (1.5 h), &Po0.05 vs. control (24 h) according to Student's t test.
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like behavior (Ohgi et al., 2013; Park et al., 2011).
The development of depressive disorders is associated with a
sustained activation of the innate immune system (Dantzer et al.,
2008), while many conditions with an underlying chronic inﬂam-
matory component, such as obesity, rheumatoid arthritis, athero-
sclerosis and type II diabetes are associated with an increased
prevalence of depressive disorders (Evans et al., 2005). Several
studies have used LPS-induced behavioral effects to clarify the
associations between neuroinﬂammation and depression (Dunn
and Swiergiel, 2005; Fu et al., 2010; Park et al., 2011). LPS-induced
behavioral effects have been shown to be time-dependent and
evident 24 h post-treatment (Ohgi et al., 2013; Park et al., 2011).Patients with major depressive disorder have lower PPI levels
when compared to healthy subjects, although PPI levels are higher
in depressed patients when compared to schizophrenic patients
(Perry et al., 2004). Deﬁcits in central inhibitory mechanisms, i.e.,
the organism's ability to inhibit or gate responses to sensory,
motor, or cognitive information are manifested in several neurop-
sychiatric disorders (Swerdlow and Geyer, 1993) and are evaluated
using the PPI test (Swerdlow and Geyer, 1993). The association
between PPI levels and LPS-induced depressive-like behavior was
tested by comparing PPI values of LPS-treated animals (i.e.,
depressive-like behavior) to those of ketamine-treated mice
(a drug known to disrupt PPI and widely employed as a pharma-
cological model of schizophrenia) (Becker and Grecksch, 2004).
Our results revealed signiﬁcantly lower PPI levels only 24 h post-
LPS treatment. Similar to previous clinical observations (Perry
et al., 2004), this decrease in PPI levels in LPS-challenged animals
was less severe than that observed in ketamine-treated mice. One
possible explanation for the observed lower PPI levels 24 h
post-LPS treatment may be the upregulation of indoleamine
2,3-dioxygenase (IDO) induced by pro-inﬂammatory cytokines,
which is known to occur 24 h post-LPS treatment (Dantzer et al.,
2008; Sublette and Postolache, 2012).
Kynurenine metabolites are products of the IDO pathway, are
involved in the pathophysiology of depression (Dantzer et al.,
2008) and their levels have been linked to changes in PPI (Fletcher
et al., 2001). Previous reports have found that the administration
of LPS did not cause PPI alterations 60–75 min post-LPS treatment
(Lockey et al., 2009). This is in agreement with our ﬁndings that
PPI levels are unchanged 1.5 h post-LPS treatment. However, a
novel later-onset (i.e., 24 h post-LPS treatment) decrease in PPI
was identiﬁed.
Preclinical studies of LPS-induced behavioral alterations pro-
vided evidence for a delayed depressive-like behavior (Fu et al.,
2010) and changes in cytokine levels are known to persist in some
areas of the brain (Dunn and Swiergiel, 2005; Dunn et al., 2005) or
may not emerge until later (up to 24 h post-LPS treatment) (Bossu
et al., 2012). In humans, administration of a bolus injection of
bacterial LPS (0.4 ng/kg) induces a pronounced transient increase
in the plasma levels of TNFα, IL-1ra, IL-6, IL-10 and cortisol, which
is accompanied by a decrease in positive mood and an increase in
anxiety (Grigoleit et al., 2011; Kullmann et al., 2012).
Although anxiety has been observed in human subjects follow-
ing LPS treatment, it is difﬁcult to translate these results to
experimental animals because anxiogenic-like behavior is often
observed during the early sickness-behavior period (Lacosta et al.,
1999; Swiergiel and Dunn, 2007), together with decreased loco-
motor activity (Swiergiel and Dunn, 2007) this may confound the
interpretation of results. We ﬁnd a similar pattern of behavior
changes; a decrease in locomotor activity was observed 1.5 h post-
LPS treatment together with anxiogenic-like behavior in EPM
testing. Although neither of these parameters differed from con-
trol mice at 24 h post-LPS treatment, we cannot rule out the
possibility that the observed anxiogenic effects during EPM testing
are inﬂuenced by a decrease in locomotor activity (Swiergiel and
Dunn, 2007).
In the present study we identify a decrease in nitrite levels in
all brain areas at 1.5 and 24 h post-LPS treatment. It has been
reported that treatment with nitric oxide (NO) synthase inhibitor
is able to increase the severity of LPS-induced sickness behavior in
rats (Connor et al., 2002). Taken together, these results suggest
that endogenous NO does not act as a mediator of LPS-induced
sickness behavior but may have a protective role, acting in an
inhibitory feedback loop to limit LPS-induced sickness. Indeed
nitrite/nitrate levels are decreased in the cerebrospinal ﬂuid of
depressive patients (Gao et al., 2012) and there is evidence to
suggest that aberrant NO neurotransmission may result in
C.S. Custódio et al. / European Journal of Pharmacology 713 (2013) 31–38 37depressive-like behaviors via the cAMP response element binding
protein (CREB) (Hu et al., 2012; Maes et al., 2009).
A role for endogenous NO in restraining over-activation of the
hypothalamic-pituitary–adrenal (HPA) axis during periods of increased
cytokine and/or neuropeptide secretion (e.g., during immune stimula-
tion) (Jankord et al., 2009; Uribe et al., 1999), may account for the
LPS-induced decrease in nitrite levels observed here. Indeed, gluco-
corticoids play an important role in coping with unpredictable insult
by maintaining allostasis (McEwen and Wingﬁeld, 2003; Romero
et al., 2009). Therefore, we can speculate that LPS-induced reductions
in brain nitrite levels may promote an increase in corticosterone
secretion and thus initially mitigate depressive-like behavior. Our
ﬁndings suggest that NO is not only involved in the development of
sickness behavior, but also may play a role in LPS-induced depressive-
like behavior.
This study identiﬁes increased IL-1β levels in the brain 1.5 and
24 h post-LPS treatment only in the PFC. The PFC plays an important
role in cognitive control, such as planning, reasoning and problem
solving (Miller and Cohen, 2001). A recent review article highlights
that in translational models, IL-1β administration elicits depressive-
like behaviors, neuroinﬂammation and neuroprogression, while
interleukin-1 receptor antagonists (e.g., IL-1R) were suggested to have
antidepressant effects and possibly attenuate neuroprogression of
severe mental disorders (Maes et al., 2012b).
In conclusion, we identify LPS-induced time-dependent altera-
tions in PPI levels, brain nitrite content and prefrontal IL-1β levels,
supporting a speciﬁc role for NO pathways in LPS-induced beha-
vioral alterations and suggest that drugs which modulate central
NO signaling may have promise as novel neurotherapeutic targets
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